Please assess the completion status of the following clinical trial:

Trial Title: Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females between the ages of 18 and 80 years admitted to a general surgery service.~2. Patients admitted for non-cardiac elective or emergency surgery or trauma.~3. A known history of type 2 diabetes mellitus \> 3 months, receiving either diet alone or any combination of oral antidiabetic agents (sulfonylureas, metformin, thiazolidinediones).~4. Subjects must have an admission blood glucose \> 140 mg and \< 400 mg/dL without laboratory evidence of diabetic ketoacidosis (serum bicarbonate \< 18 mEq/L or positive serum or urinary ketones).~Exclusion Criteria:~1. Subjects with increased blood glucose concentration, but without a known history of diabetes (stress hyperglycemia).~2. Subjects with a history of diabetic ketoacidosis and hyperosmolar hyperglycemic state, or ketonuria.~3. Acute critical illness or CABG surgery expected to require prolonged admission to a critical care unit (ICU, CCU, SICU, Neuro ICU).~4. Patients with clinically relevant hepatic disease or impaired renal function, as shown by a serum creatinine ≥ 3.5 mg/dl.~5. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.~6. Female subjects are pregnant or breast feeding at time of enrollment into the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Glargine once daily plus glulisine given before meals plus supplemental glulisine for BG \> 140
- 2 (Type: ACTIVE_COMPARATOR): Sliding scale regular insulin four-times daily achs.

Based on this trial design, predict the completion outcome and termination type (if applicable).